Single ascending dose study of the safety, tolerability, and pharmacokinetics of FXR-450 administered orally to healthy Japanese male subjects.

Trial Profile

Single ascending dose study of the safety, tolerability, and pharmacokinetics of FXR-450 administered orally to healthy Japanese male subjects.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2010

At a glance

  • Drugs Turofexorate isopropyl (Primary)
  • Indications Lipid metabolism disorders
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Aug 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 21 Jun 2010 Planned number of patients added to 56 as reported by ClinicalTrials.gov.
    • 21 Jun 2010 Actual end date (Feb 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top